New obesity drugs are coming
a year ago
- #obesity
- #GLP-1 agonists
- #weight-loss drugs
- Kristian Cook's struggle with obesity and his participation in a clinical trial combining semaglutide (Ozempic/Wegovy) with an experimental muscle-preserving drug, bimagrumab.
- Concerns about muscle loss with GLP-1 agonists like semaglutide and the development of over 100 anti-obesity drug candidates targeting various pathways.
- The success of semaglutide and tirzepatide (Zepbound/Mounjaro) in the obesity drug market, projected to exceed $100 billion by 2030, despite limitations like side effects and muscle loss.
- Emerging therapies aim to improve weight loss, tolerability, and long-term effects, with drugs like orforglipron, CagriSema, survodutide, and retatrutide expected to hit the market by 2028.
- Tirzepatide's dual action on GLP-1 and GIP hormones leads to superior weight loss compared to semaglutide, inspiring new drug developments targeting multiple pathways.
- Potential risks and uncertainties with new obesity drugs, including effects on bone health and long-term metabolic impacts, leading some clinicians to prefer bariatric surgery.
- Exploration of alternative drug delivery methods, such as once-monthly injectables and oral GLP-1 pills like orforglipron, to improve patient adherence.
- Genetic research uncovering rare variants linked to low body weight and healthier fat distribution, inspiring new drug targets beyond gut hormones.
- Renewed interest in cannabinoid receptor CB1 inhibitors, like monlunabant, aiming to avoid brain-related side effects while maintaining metabolic benefits.